‘Drastic’ Japan Price Reforms Hitting R&D Incentives, Plans - EFPIA
European research-based pharma group proposes reconsideration of Japan’s revised pricing system, warning it is already affecting corporate R&D decisions and will stifle industry investment, innovation and patient access to new therapies if incentives are not improved.
You may also be interested in...
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
A look back at the Scrip stories that piqued the most interest for our readers in 2018.
Following pricing reforms earlier this year that industry saw as generally unfavorable, major pharma associations in Japan present a united front in calling for a broad range of policy revisions to promote an ecosystem that better fosters and rewards innovation.